Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Refractory AML
NCT00880269Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of panobinostat in acute myeloid leukemia (AML), sponsored by Novartis. Started Aug 2009; status: completed.
02
Drugs
panobinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00880269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880269.